# ARD103

Source: https://onco.cc/drugs/ard103/  
OnCo record `ard103` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

ARD103 is a car-t cell therapy from ARCE Therapeutics, Inc., in registered phase 2 trials for acute myeloid leukaemia, myelodysplastic syndromes / neoplasms.

## Summary

ARD103 is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by ARCE Therapeutics, Inc., in acute myeloid leukaemia, myelodysplastic syndromes / neoplasms. A chimeric antigen receptor T-cell therapy, as described in the registry record: the patient's T cells are engineered to recognise a tumour antigen and infused back. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest; registry-only
- Code: ARD103
- Modality: CAR-T cell therapy
- Mechanism: A chimeric antigen receptor T-cell therapy, as described in the registry record: the patient's T cells are engineered to recognise a tumour antigen and infused back.

## Sources

- ClinicalTrials.gov: trials of ARD103: https://clinicaltrials.gov/search?intr=ARD103

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [Myelodysplastic syndromes / neoplasms (MDS)](https://onco.cc/cancers/mds/)
- trials: [Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS](https://onco.cc/trials/nct06680752/)

---
JSON: https://onco.cc/api/v1/entities/ard103.json